Opinion

Video

Overview of Efficacy and Safety Data for Current CLL Treatment Options

A general overview of efficacy and safety data for current treatment options for patients with chronic lymphocytic leukemia.

Related Videos
1 expert is featured in this series.
Image of man with brown hair.
Image of a man wearing a black button-up shirt.
Related Content
Image of red blood cells.
December 18th 2024

Imbruvica-Venetoclax Shows Promise in Managing CLL

Spencer Feldman
A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated CLL, an expert explained.
A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More
January 22nd 2024

A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More

Alex Biese Brielle Benyon
We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.
Image of a heart monitor.
December 9th 2024

Heart Risk May Occur Less With Some BTK Inhibitors in B-Cell Blood Cancers

Ashley Chan
In patients with certain B-cell blood cancers, heart-related side effects may occur less after receiving second-generation BTK inhibitors.
CURE Talks Cancer podcast
December 31st 2020

The Treatment Journey of a Patient with CLL

Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Mark Hoffman, a patient with chronic lymphocytic leukemia, about his diagnosis and treatment journey.
Illustration of blood cells.
December 9th 2024

Calquence Plus Venclexta Combo May Improve Survival in Frontline CLL

Kristie L. Kahl
Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia.
Image of woman with black hair.
November 12th 2024

Managing Trodelvy’s Side Effects Through Dose Adjustment

Spencer Feldman
An expert told CURE that Trodelvy's side effects, such as neutropenia and fatigue, can often be managed through dose adjustments.